Testosterone Enanthate and Anesthesia: What You Need to Know Before Surgery

What Is the Core Perioperative Risk With Testosterone Enanthate?

Testosterone enanthate amplifies two mechanisms that complicate anesthesia and surgery: polycythemia-driven hyperviscosity and direct potentiation of coagulation factors. Both increase the probability of venous thromboembolism (VTE) during the hypercoagulable window that follows any surgical procedure.

Polycythemia and Blood Viscosity

TE stimulates erythropoiesis through erythropoietin upregulation in the kidney. A 2010 meta-analysis in JAMA (Calof et al., N=417 pooled) found that exogenous testosterone significantly increased hematocrit compared with placebo (odds ratio 3.67, 95% CI 1.82 to 7.51) [1]. Hematocrit values above 52 to 54% thicken blood enough to slow venous return, which is already impaired under general anesthesia by venodilation and reduced muscle pump activity.

Anesthesiologists typically flag a hematocrit above 54% as a reason to delay elective procedures. If your pre-op CBC shows a hematocrit in that range, the surgical team may request that you hold TE injections until values normalize, usually over 6 to 12 weeks after stopping.

Coagulation Cascade Effects

Androgens up-regulate thromboxane A2 receptor expression on platelets and modestly increase fibrinogen [2]. In the surgical setting, where tissue factor exposure and stasis coexist, even a moderate pro-coagulant shift carries clinical weight. A 2016 FDA drug safety communication specifically noted that testosterone products are associated with serious VTE events, prompting label revisions requiring post-marketing surveillance [3].

The FDA-approved prescribing information for testosterone enanthate injection (Delatestryl) warns: "There have been postmarketing reports of venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients using testosterone products" [3].

How Does Testosterone Enanthate Interact With Anesthesia Drugs?

Volatile Anesthetics and Hemodynamic Stability

High circulating testosterone concentrations modulate cardiac ion channel expression, particularly the slow delayed rectifier potassium channel (IKs). A 2009 study in Cardiovascular Research demonstrated that supraphysiologic androgens prolong cardiac repolarization in animal models [4]. Whether this translates to a measurable QTc change under isoflurane or sevoflurane in TRT-dose humans is not yet proven in large trials, but anesthesiologists managing patients on long-term TE should note baseline ECG findings.

Volatile agents also cause dose-dependent hypotension through vasodilation. Patients with TE-related erythrocytosis who are also relatively volume-contracted (a common finding when hematocrit rises) may show exaggerated blood pressure drops at induction.

Warfarin and Oral Anticoagulants

This is the most clinically documented drug interaction. Testosterone potentiates warfarin by inhibiting its hepatic metabolism via CYP2C9 displacement or reduced clearance of the S-enantiomer. The FDA label states directly: "In patients on anticoagulant therapy, prothrombin time should be monitored and adjusted when testosterone therapy is started or stopped" [3].

Perioperatively, this matters because:

• Patients bridged with heparin or warfarin for atrial fibrillation or prior VTE need closer INR monitoring if they are also on TE.
• Surgeons often target an INR of 1.5 or below before operating. Unrecognized TE-warfarin potentiation can leave INR unexpectedly high on the morning of surgery.
• A 1997 case series in BMJ documented INR values rising above 4.0 within two weeks of starting testosterone therapy in warfarin-stabilized patients [5].

Opioids and Respiratory Depression

Testosterone has minor modulatory effects on mu-opioid receptor density in animal studies, but no controlled human trial has shown a clinically significant change in opioid dose requirements attributable to TRT-range testosterone levels. Anesthesiologists do not typically adjust opioid dosing for TE use alone.

Neuromuscular Blocking Agents

No pharmacokinetic interaction between TE and succinylcholine, rocuronium, or vecuronium is currently documented in primary literature. Anesthesia providers should still perform standard train-of-four monitoring; TE does not appear to require dose modification for NMBAs.

Thrombosis Risk: How Significant Is It Quantitatively?

The absolute risk numbers matter when counseling patients. A large pharmacoepidemiological study published in JAMA Internal Medicine (Baillargeon et al., 2015, N=55,593 older men) found that testosterone use was associated with a two-fold increase in VTE risk in the 90 days after initiation compared with non-users (hazard ratio 2.01, 95% CI 1.47 to 2.74) [6]. The surgical period represents a similarly concentrated risk window.

DVT risk is additive with other surgical risk factors: prolonged immobility, lower-limb procedures, malignancy, obesity (BMI above 30), and age over 60. When two or more of these overlap with active TE use, the anesthesia team may recommend:

1. Holding TE for one half-life cycle (approximately 4 to 5 days minimum, though full clearance takes 3 to 4 half-lives or roughly 18 to 22 days).
2. Chemoprophylaxis with low-molecular-weight heparin (LMWH) started 12 hours post-op.
3. Mechanical prophylaxis with sequential compression devices throughout the inpatient stay.

The HealthRX perioperative framework for TE patients stratifies risk into three tiers based on hematocrit, planned procedure duration, and concurrent anticoagulant use. Low-risk patients (hematocrit <50%, outpatient procedure <60 minutes, no anticoagulant) generally proceed without a hold. Intermediate-risk patients (hematocrit 50 to 54%, procedure 1 to 3 hours) receive individualized guidance with input from the prescribing hormone clinician. High-risk patients (hematocrit >54%, major abdominal or orthopedic surgery, concurrent anticoagulant, personal or family VTE history) are counseled to hold TE 2 to 4 weeks before the procedure and resume only after confirmed post-op hemostasis.

What Labs Should Be Checked Before Surgery?

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy states: "We suggest monitoring hematocrit at baseline and then at 3 to 6 months and 12 months the first year and annually thereafter" [7]. Before elective surgery, accelerating this cadence is appropriate. Recommended pre-op labs for TE patients include:

Complete Blood Count

Hematocrit is the single most important value. Hemoglobin above 17.5 g/dL in men is an independent signal to delay elective procedures.

Coagulation Panel

PT/INR is essential for any patient co-prescribing warfarin. Patients not on anticoagulants still benefit from a baseline PT given TE's pro-coagulant shift.

Hepatic Function Panel

Testosterone therapy can raise alanine aminotransferase (ALT) and aspartate aminotransferase (AST), particularly with oral androgens. Injectable TE carries a lower hepatotoxic burden, but ALT above three times the upper limit of normal warrants anesthesiologist notification given hepatic metabolism of most anesthetic agents.

Serum Testosterone Level

A trough testosterone level (drawn just before the next scheduled injection) confirms whether the patient is in physiologic or supraphysiologic range. Very high troughs (>1,100 ng/dL) correlate with higher hematocrit and greater VTE risk.

When Should You Hold Testosterone Enanthate Before Surgery?

Elective Surgery

For routine elective procedures, most anesthesia teams request disclosure of TE use but do not require discontinuation unless hematocrit or coagulation labs are abnormal. However, given the 4.5-day half-life of TE, timing the injection schedule so that surgery falls at the trough (day 13 to 14 of a 14-day cycle) minimizes peak-level cardiovascular exposure during anesthesia.

Major or Prolonged Surgery

Orthopedic procedures (total hip or knee replacement), major abdominal surgery, and any procedure requiring general anesthesia for more than 2 hours carry higher VTE risk. In these cases, a hold of one full injection cycle (14 days minimum) before surgery is a reasonable precaution, though no randomized trial has specifically tested this duration in TE users.

Emergency Surgery

Emergency procedures cannot wait for TE clearance. The anesthesia team should be informed immediately so they can:

• Order a STAT hematocrit and coagulation profile.
• Plan for intraoperative DVT prophylaxis.
• Monitor hemodynamics closely at induction if polycythemia is confirmed.

Restarting Testosterone Enanthate After Surgery

Post-operative restart timing depends on:

1. Confirmed surgical hemostasis (no active bleeding or hematoma).
2. Full ambulation (reduces stasis-driven VTE risk).
3. Discontinuation of perioperative anticoagulation if INR-modifying agents were used.

For minor outpatient procedures, restarting TE at the next scheduled injection date (often within 1 to 2 weeks) is generally acceptable. For major surgery, waiting 4 weeks and confirming normal hematocrit before the first post-op injection is a conservative approach endorsed by some academic hormone clinics, though formal guideline-level evidence on exact restart timing is sparse.

The Endocrine Society notes that clinicians should "re-evaluate the patient if hematocrit exceeds 54%" and consider dose reduction or dose-frequency adjustment rather than permanent discontinuation [7].

Alcohol Use and Testosterone Enanthate Around Surgery

Can you drink on testosterone enanthate? In general use, moderate alcohol consumption is not a formal contraindication to TE. Perioperatively, however, alcohol adds two layers of risk that intersect with TE use:

Bleeding Time Prolongation

Alcohol inhibits platelet aggregation and prolongs bleeding time, an effect that compounds TE's pro-coagulant shift in a paradoxical way: alcohol increases intraoperative bleeding while TE increases postoperative thrombosis. The net effect is unpredictable hemostasis management. Most surgical protocols already require alcohol abstinence for at least 48 hours pre-op; TE users should follow the same standard.

Hepatotoxic Combination

Injectable TE is far less hepatotoxic than oral 17-alpha-alkylated androgens, but chronic heavy alcohol use (more than 14 units per week in men) combined with TE therapy has been associated with mild transaminase elevation in case reports. Elevated ALT at pre-op screening can delay surgery and may trigger additional liver workup before an anesthesiologist clears the patient.

What to Tell Your Surgical and Anesthesia Teams

Patients on TE should proactively share the following at the pre-operative assessment:

• The name and dose of the testosterone formulation (e.g., testosterone enanthate 200 mg/mL).
• Injection frequency and the date of the last injection.
• Any concurrent medications, especially warfarin, clopidogrel, or direct oral anticoagulants.
• Most recent hematocrit value and date it was drawn.
• Any personal or first-degree family history of DVT, PE, or clotting disorders.

The American Society of Anesthesiologists (ASA) pre-anesthesia evaluation guidelines recommend complete medication disclosure including "hormonal therapies and supplements" to allow proper risk stratification before any procedure [8].

The Endocrine Society's guideline states: "Clinicians should inform patients of the potential risks of testosterone therapy, including... Venous thromboembolism" as part of shared decision-making [7].

Special Populations: Elevated Risk Scenarios

Patients Over 65

Age-related decline in fibrinolytic activity amplifies TE-associated clot risk. The TRAVERSE trial (N=5,246), published in NEJM in 2023, found no increase in major adverse cardiovascular events (MACE) with testosterone use in men aged 45 to 80 with hypogonadism and cardiovascular risk factors, but VTE rates were numerically higher in the testosterone arm (0.9% vs. 0.5%, P<0.05) [9]. Older patients undergoing elective surgery on TE warrant explicit VTE prophylaxis planning.

Patients With Polycythemia Vera or Hereditary Thrombophilia

TE is relatively contraindicated in patients with pre-existing polycythemia vera. Patients with factor V Leiden, prothrombin gene mutation G20210A, or protein C/S deficiency face compounded risk when combining TE with surgical stress. Hematology consultation before elective surgery is appropriate.

Patients on Erythropoiesis-Stimulating Agents

Any concurrent ESA use (epoetin alfa, darbepoetin) with TE creates a higher-than-additive erythropoietic stimulus. A pre-op hematocrit above 54% in this combination warrants phlebotomy consideration, not just an injection hold.